by Raymond J. Bergeron, Jan Wiegand, and Gary M. Brittenham

Slides:



Advertisements
Similar presentations
Update on Imaging: Detection of Iron in Liver and Heart Tim St. Pierre, BSc, PhD Professor School of Physics The University of Western Australia Crawley,
Advertisements

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
Induction of Shock After Intravenous Injection of Adenovirus Vectors: A Critical Role for Platelet-activating Factor  Zhili Xu, Jeffrey S. Smith, Jie.
Volume 67, Issue 2, Pages (February 2005)
Net metabolic rate of walking at 1. 5 m/s vs
The influence of high-altitude living on body iron
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
Alternate designs for conduct and analysis of phase I cancer trials
by Seth Rivera, Lide Liu, Elizabeta Nemeth, Victoria Gabayan, Ole E
by Masako Moriuchi, Hiroyuki Moriuchi, and Anthony S. Fauci
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13 by Koichi Kokame, Masanori Matsumoto, Yoshihiro.
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment by James L. Rubenstein, Dan Combs, Jay Rosenberg, Arthur Levy, Michael McDermott,
Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia by Hironori.
by Jurgen Seppen, Simon C. Barry, Brandon Harder, and William R. A
Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic Pentasaccharide by J.M. Herbert, J.P. Hérault, A. Bernat,
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Platelet depletion by anti-CD41 (αIIb) mAb injection early but not late in the course of disease protects against Plasmodium berghei pathogenesis by altering.
by James O. Armitage Blood Volume 92(12): December 15, 1998
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Iron-Chelating Therapy and the Treatment of Thalassemia
by Wim K. Bleeker, Jessica L. Teeling, and C. Erik Hack
How I treat elderly patients with myeloma
Desferrioxamine-chelatable iron, a component of serum non–transferrin-bound iron, used for assessing chelation therapy by William Breuer, Marieke J. J.
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage by Daphne Stewart, Mansze Kong, Valery Novokhatny, Gary Jesmok, and Victor.
by Kirsteen H. Maclean, John L. Cleveland, and John B. Porter
Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation by Akio Mizutani, Kenji Okajima, Mitsuhiro.
by John C. Wood, Pinggao Zhang, Hugh Y
EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models by L. Danielle Johnston, Sarah Knutson, Natalie Warholic, Christine.
Increased Phagocyte FcγRI Expression and Improved Fcγ-Receptor–Mediated Phagocytosis After In Vivo Recombinant Human Interferon-γ Treatment of Normal Human.
Setting the table for macrophages
Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Xingwei Sui, Sanford B. Krantz, and Zhizhuang Zhao
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcript by Madhumita.
by Jun Yuan, David B. Lovejoy, and Des R. Richardson
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia by.
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population by Sumithira Vasu,
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A by Atsushi Muto, Kazutaka Yoshihashi,
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
by Anita Hill, Peter Hillmen, Stephen J
Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors by Teal S. Hallstrand,
Molecular Therapy - Nucleic Acids
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency  Carrie.
by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu T. Kalathottukaren, A.
Volume 67, Issue 2, Pages (February 2005)
Molecular Therapy - Nucleic Acids
Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients  Denis Fouque, Susy C. Peng, Eshan Shamir, Joel.
Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats  Sateesh Khandavilli, Ramesh Panchagnula 
Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.
by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E
(A) Mean CoP and maximum XcoM during the stride as a function of push magnitude. (A) Mean CoP and maximum XcoM during the stride as a function of push.
Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
ATL-801 treatment increases insulin sensitivity in KKAY mice.
Expression of Prostacyclin Receptor in Human Megakaryocytes
Molecular Therapy - Nucleic Acids
GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.
A binding relationship with thrombin
Efficiencies of conversion of BSE GR to urinary SF and DTC in two populations. Efficiencies of conversion of BSE GR to urinary SF and DTC in two populations.
The effect of a change in the expression level of the receptor and the binding affinity on the subcutaneous bioavailability of mAbs. The effect of a change.
Consistency of conversion of GR to urinary ITC in 3 high converter phenotypes who were tested on 5 to 7 occasions (selected from the 131 determinations.
Patient Tregs express normal levels of suppression.
Examples of item response theory item characteristics curves.
Perception of indications for referral to a nephrologist among internal medicine residents according to the postgraduate year (PGY). Perception of indications.
Presentation transcript:

by Raymond J. Bergeron, Jan Wiegand, and Gary M. Brittenham HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy by Raymond J. Bergeron, Jan Wiegand, and Gary M. Brittenham Blood Volume 91(4):1446-1452 February 15, 1998 ©1998 by American Society of Hematology

Structures of the iron chelators chosen for evaluation: deferoxamine B (DFO) andN,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid dihydrochloride dihydrate (HBED). Structures of the iron chelators chosen for evaluation: deferoxamine B (DFO) andN,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid dihydrochloride dihydrate (HBED). Raymond J. Bergeron et al. Blood 1998;91:1446-1452 ©1998 by American Society of Hematology

Time course of mean biliary iron excretion in normal rats after administration of DFO by SC injection and after administration of HBED by gavage or by SC injection. Time course of mean biliary iron excretion in normal rats after administration of DFO by SC injection and after administration of HBED by gavage or by SC injection. Both chelators were given at a dose of 150 μmol/kg body weight. The peak amounts of iron excreted with SC HBED (*) were more than twofold greater than the peak iron excretion after either SC DFO or HBED given by gavage (P < .05 at 3 hours and P < .01 at 6 hours). Raymond J. Bergeron et al. Blood 1998;91:1446-1452 ©1998 by American Society of Hematology

Mean net iron excretion in normal rats after administration of DFO by SC injection and after administration of HBED by gavage or by SC injection. Mean net iron excretion in normal rats after administration of DFO by SC injection and after administration of HBED by gavage or by SC injection. Excretion is shown as μg Fe/kg body weight on the scale of the left vertical axis and as efficiency of chelation (net iron excretion/total iron-binding capacity of chelator administered, expressed as a percent) on the right vertical axis. Both chelators were given at a dose of 150 μmol/kg body weight. Raymond J. Bergeron et al. Blood 1998;91:1446-1452 ©1998 by American Society of Hematology

Mean net iron excretion in C apella monkeys with iron overload (see text) after administration of DFO by SC injection and of HBED by SC injection. Mean net iron excretion in C apella monkeys with iron overload (see text) after administration of DFO by SC injection and of HBED by SC injection. Excretion is shown as μg Fe/kg body weight on the scale of the left vertical axis and as efficiency of chelation (net iron excretion/total iron-binding capacity of chelator administered, expressed as a percent) on the right vertical axis. Both chelators were given at a dose of 150 μmol/kg body weight. For convenience, the result of our previously published study31of the oral administration of HBED in phosphate buffer to C apella monkeys with a similar magnitude of iron overload is also shown; this previous result is indicated by an asterisk. Raymond J. Bergeron et al. Blood 1998;91:1446-1452 ©1998 by American Society of Hematology